Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 862-866

  Veenstra, Jan ^c   Williams, Ian G ^d   Colebunders, Robert ^d   Dorrell, Lucy ^d   Tchamouroff, Stephan E ^d   Patou, Gary ^a,b   Lange, Joep M A ^d   Weller, Ian V D ^d   Goeman, Johan ^d   Uthayakumar, Sundaralingam ^d   Gow, Irene R ^a   Weber, Jonathan N ^d   Coutinho, Roel A ^d  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

^d Dept of Public Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; RECOMBINANT VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS PARTICLE;

EID: 19244362593     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.862     Document Type: Article

References (15)

1. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987;327:473-6.
2. Lange JMA, Paul DA, Huisman HG, et al. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J 1986;293:1459-62.
3. Weber JN, Clapham PR, Weiss RA, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera an associating of anti-gag antibody with prognosis. Lancet 1987;1:119-22.
4. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 1991;302:23-6.
5. Hogervorst E, Jurriaans S, de Wolf F, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995;171:811-21.
6. Foster SM, Osborn LM, Cheingsong-Popov R, et al. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. AIDS 1987;1:235-40.
7. De Wolf F, Goudsmit J, Paul DA, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J 1987;295:569-72.
8. Martin SJ, Vyakarnam A, Cheingsong-Popov R, et al. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24 specific cellular and humoral immune responses. AIDS 1993;7:1315-23.
9. Taves DR. Minimisation: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443-53.
10. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. A rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma; application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
11. Koot M, Vos AH, Keet IPM, et al. HIV-1 biological phenotype in longterm infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
12. Redfield RR, Birx DL, Ketter N, et al. A phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-84.
13. Ho DD. HIV-1 viraemia and influenza [letter]. Lancet 1992;339:1549.
14. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
15. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity viral DNA and percentage of CD4 cells. J Infect Dis 1994;169:1256-64.